501 related articles for article (PubMed ID: 33149569)
1. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
6. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
[TBL] [Abstract][Full Text] [Related]
7. Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β
Naya IP; Tombs L; Lipson DA; Compton C
Adv Ther; 2018 Oct; 35(10):1626-1638. PubMed ID: 30191464
[TBL] [Abstract][Full Text] [Related]
8. Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Kalhan R; Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
Int J Chron Obstruct Pulmon Dis; 2021; 16():1149-1161. PubMed ID: 33911860
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Czira A; Requena G; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
[TBL] [Abstract][Full Text] [Related]
11. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
Moretz C; Cole AL; Mu G; Wu B; Guisinger A; Liu Y; Hahn B; Baylis L
Int J Chron Obstruct Pulmon Dis; 2020; 15():2207-2215. PubMed ID: 32982213
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
Sethi S; Clark B; Bengtson LGS; Buysman EK; Palli S; Sargent A; Shaikh A; Ferguson GT
Int J Chron Obstruct Pulmon Dis; 2023; 18():625-641. PubMed ID: 37155497
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Siler TM; Kerwin E; Singletary K; Brooks J; Church A
COPD; 2016; 13(1):1-10. PubMed ID: 26451734
[TBL] [Abstract][Full Text] [Related]
16. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
17. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
18. Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.
Maltais F; Vogelmeier CF; Kerwin EM; Bjermer LH; Jones PW; Boucot IH; Lipson DA; Tombs L; Compton C; Naya IP
Respir Med; 2022; 200():106918. PubMed ID: 35803172
[TBL] [Abstract][Full Text] [Related]
19. DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
Singh D; Litewka D; Páramo R; Rendon A; Sayiner A; Tanni SE; Acharya S; Aggarwal B; Ismaila AS; Sharma R; Daley-Yates P
Adv Ther; 2023 Oct; 40(10):4282-4297. PubMed ID: 37382864
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
